ArticleWorld journal of surgical oncology2025
Evaluating long-term outcomes after cytoreductive surgery for colorectal peritoneal metastasis: do long survivors really exist?
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Early postoperative morbidity and short-term outcomes after cytoreductive surgery and HIPEC for peritoneal surface malignancies: initial single-center experience from Palestine.Frontiers in oncology · 2026Article
- Long-term survival and prognostic factors after repeated metastasectomies in metastatic colorectal cancer: a 15-years retrospective study.The oncologist · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated improved overall survival (OS) and disease-free survival (DFS) in carefully selected patients with peritoneal metastases from colorectal cancer (CRC-PM). The primary aim of this retrospective study was to identify patients treated with CRS + HIPEC who achieved long-term survival and to analyze the factors most strongly associated with prolonged survival.
methodsAmong those eligible for CRS + HIPEC, a group of patients with adequate follow-up was evaluated and divided into two groups: the long-term survival group (OS > 48 months) and the average-term survival group (OS < 48 months). A comparative analysis was performed between the two groups to evaluate which factors might be associated with an increased likelihood of long-term survival. Propensity score matching (PSM) was employed to homogenize patients based on peritoneal cancer index (PCI) and extensive small bowel involvement. A further analysis was conducted to assess the differences in recurrence behavior between the two groups.
resultsDuring the study period, 116 patients underwent CRS + HIPEC. The median OS for the entire sample was 52 months. Among the 63 patients with at least 4 years of follow-up, 32 were identified as part of the average survival group (AS-G), while 31 were classified in the long-survival group (LS-G). DFS and survival after recurrence were statistically higher in the LS-G compared to the AS-G. Higher PCI, BRAF V600E mutation, right-sided primary tumor location, small bowel involvement, and mucinous histology were statistically more frequent in the AS-G compared to the LS-G. After PSM analysis, the absence of BRAF V600E mutation and the non-mucinous histology were significantly associated with long-term survival.
conclusionsLong-term survival can potentially be achieved in patients with peritoneal metastasis from colorectal cancer (CRC) treated with CRS and HIPEC, often resulting in prolonged disease-free periods and less aggressive disease progression if recurrence occurs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.